Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
119 hedge funds and large institutions have $3.3B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 41 increasing their positions, 39 reducing their positions, and 21 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less call options, than puts
Call options by funds: $17.8M | Put options by funds: $18.7M
5% less funds holding
Funds holding: 125 → 119 (-6)
22% less capital invested
Capital invested by funds: $4.23B → $3.3B (-$924M)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$46.8M |
| 2 |
Millennium Management
New York
|
+$13.6M |
| 3 |
BNP Paribas Asset Management
Paris,
France
|
+$12.4M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.3M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$9.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$27.7M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$23.1M |
| 3 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$10.3M |
| 4 |
Morgan Stanley
New York
|
-$9.71M |
| 5 |
Alkeon Capital Management
New York
|
-$9.62M |
CERE Hedge Fund Activity: Q1 2023 in Review
119 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q1 2023, worth a combined $3.3B — down 22% from $4.23B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CERE and 15 opened new positions — a net loss of 6 holders — while 39 trimmed existing stakes and 41 added.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $46.8M. The largest seller was Federated Hermes, cutting an estimated $27.7M.
- 119 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q1 2023, down from 125 in Q4 2022.
- Funds reported $3.3B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q1 2023, down 22% quarter-over-quarter.
- 15 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q1 2023 and 21 closed out, a net change of -6 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q1 2023 was Paradigm Biocapital Advisors, an estimated $46.8M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q1 2023 was Federated Hermes, an estimated $27.7M sold.
Based on aggregated 13F filings for Q1 2023.